A new robotic eye surgery device developed by Moran’s Paul S. Bernstein, MD, PhD, and the Ï㽶ÊÓƵ of Utah Magnetic & Medical Robotics Laboratory aims to transform retinal surgery by...
Publishing in the prestigious journal Nature Communications, Moran's latest AMD research points the field away from a liver-produced protein others had identified as a promising therapeutic target.
The John A. Moran Eye Center’s Sharon Eccles Steele Center for Translational Medicine (SCTM) is connecting the dots between genetics and disease and developing personalized treatments for age-related macular degeneration...
Researchers studying age-related macular degeneration (AMD) have clarified what constitutes genetic risk or protection for the blinding disease, showing that certain forms of protection amount to an "ace in the...
A research team including John A. Moran Eye Center scientists has identified reading ability and reading speed as key measures for evaluating visual decline in patients with dry, late-stage age-related...
A software based on artificial intelligence (AI) developed in collaboration with John A. Moran Eye Center physician-scientists Steffen Schmitz-Valckenberg, MD, and Monika Fleckenstein, MD, could assist age-related macular degeneration (AMD)...
Retinal specialist Steffen Schmitz-Valckenberg, MD, an internationally recognized expert on age-related macular degeneration (AMD), has joined the John A. Moran Eye Center at the Ï㽶ÊÓƵ of Utah.
New research from the John A. Moran Eye Center at the Ï㽶ÊÓƵ of Utah highlights a little-known phenomenon that can produce vivid yet harmless hallucinations among older adults as America’s...
The John A. Moran Eye Center at the Ï㽶ÊÓƵ of Utah today announced that Voyant Biotherapeutics, LLC, a company formed out of its Center for Translational Medicine (CTM), has signed...
A Ï㽶ÊÓƵ of Utah researcher and ophthalmologist helped confirm important findings from a group of Icelandic scientists who uncovered a rare risk locus for age-related macular degeneration (AMD).
